Prenetics' IM8 Unit Posts 288% Revenue Surge, Raises Full-Year Outlook
Event summary
- IM8 revenue grew 359% YoY to $45M in Q2 2026, marking six consecutive record quarters
- Prenetics raised FY 2026 IM8 revenue guidance to $220–230M from previous $180–190M
- July saw $20.9M in IM8 revenue, annualizing to $251M run-rate
- Consolidated adjusted free cash flow turned positive in July, expected to remain so
The big picture
Prenetics' IM8 unit is redefining the premium supplement market with rapid scaling, leveraging celebrity partnerships and direct-to-consumer distribution. The company's strategic pivot to focus on consumer health—divesting non-core assets like ACT Genomics—positions it for continued hypergrowth. The $400M+ IM8 revenue guidance for 2027 signals aggressive expansion plans in an increasingly competitive wellness sector.
What we're watching
- Growth Sustainability
- Whether IM8 can maintain its explosive 359% YoY revenue growth rate through product launches and expanding customer base
- Cash Flow Stability
- The pace at which positive adjusted free cash flow becomes consistent across quarters beyond Q3
- Market Expansion
- How IM8's international shipping to 46 countries will impact revenue diversification and operational complexity